New Molecule May Open New Therapeutic Pathway Against Brain Cancer
Researchers at Brown University Health have identified a molecule that could potentially alter how glioblastoma responds to treatment. Glioblastoma is the deadliest and most prevalent form of brain cancer affecting adults, with a five-year survival rate of just 5%-10%.
The molecule, designated miR-181d, is a type of microRNA that appears to work through two separate biological mechanisms. Early findings suggest it could open treatment to patients currently beyond the reach of existing therapies. Brown University Health’s study began with an unusual patient group: individuals who survive the disease far longer than their prognosis would predict.
The team analyzed hundreds of tumor samples in total, a scale of data that made it possible to identify molecular patterns distinguishing long-term survivors from typical cases. Examination of the outlier tumors showed these patients carried substantially elevated concentrations of miR-181d.
That pattern prompted investigators to explore what the molecule was doing biologically and why its presence correlated so strongly with extended survival.
One of miR-181d’s two mechanisms targets the cancer’s DNA repair capacity. Radiation and chemotherapy inflict damage on tumor cell DNA as their primary mode of action. Most glioblastoma cells can activate a repair mechanism centered on a protein called RAD51, allowing the cancer to persist.
miR-181d was found to inhibit RAD51, depriving tumor cells of their primary repair tool. Patient data showed a clear relationship: those whose tumors expressed lower RAD51 activity had substantially better outcomes.
Immune activation is the second mechanism. When applied to tumors ahead of radiation in laboratory settings, miR-181d contributed to shrinkage. Separately, it appeared to instruct the immune system to maintain an ongoing campaign against the cancer after treatment concluded. That kind of durable engagement is uncommon in brain cancer, where immune responses typically fade once active treatment ends.
Researchers found evidence suggesting miR-181d raises the probability of that sustained response taking hold.
Clark Chen, the study’s senior author, directs the Brain Tumor Program at Brown University Health. Chen and his team have investigated this molecule and the exceptional responder population for more than a decade. His work positions miR-181d as bridging the two domains most critical to glioblastoma survival: resistance to treatment and evasion of immune attack.
He argues that miR-181d therapy could extend the survival advantage currently seen only in exceptional cases to a wider group of patients. Published in the journaliScience in March 2026, the work brought together institutions including the University of Minnesota, Johns Hopkins University, and the International Institute of Information Technology.
Planning is underway for a clinical trial testing direct surgical delivery of the molecule into the tumor. Success would establish whether the molecule’s dual mechanism produces durable survival gains for patients beyond the exceptional responder group. This study is likely to provide exciting insights to other companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are also engaged in the quest for better treatments against glioblastoma and other primary and secondary brain cancers.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
Researchers at Brown University Health have identified a molecule that could potentially alter how glioblastoma responds to treatment. Glioblastoma is the deadliest and most prevalent form of brain cancer affecting adults, with a five-year survival rate of just 5%-10%.
The molecule, designated miR-181d, is a type of microRNA that appears to work through two separate biological mechanisms. Early findings suggest it could open treatment to patients currently beyond the reach of existing therapies. Brown University Health’s study began with an unusual patient group: individuals who survive the disease far longer than their prognosis would predict.
The team analyzed hundreds of tumor samples in total, a scale of data that made it possible to identify molecular patterns distinguishing long-term survivors from typical cases. Examination of the outlier tumors showed these patients carried substantially elevated concentrations of miR-181d.
That pattern prompted investigators to explore what the molecule was doing biologically and why its presence correlated so strongly with extended survival.
One of miR-181d’s two mechanisms targets the cancer’s DNA repair capacity. Radiation and chemotherapy inflict damage on tumor cell DNA as their primary mode of action. Most glioblastoma cells can activate a repair mechanism centered on a protein called RAD51, allowing the cancer to persist.
miR-181d was found to inhibit RAD51, depriving tumor cells of their primary repair tool. Patient data showed a clear relationship: those whose tumors expressed lower RAD51 activity had substantially better outcomes.
Immune activation is the second mechanism. When applied to tumors ahead of radiation in laboratory settings, miR-181d contributed to shrinkage. Separately, it appeared to instruct the immune system to maintain an ongoing campaign against the cancer after treatment concluded. That kind of durable engagement is uncommon in brain cancer, where immune responses typically fade once active treatment ends.
Researchers found evidence suggesting miR-181d raises the probability of that sustained response taking hold.
Clark Chen, the study’s senior author, directs the Brain Tumor Program at Brown University Health. Chen and his team have investigated this molecule and the exceptional responder population for more than a decade. His work positions miR-181d as bridging the two domains most critical to glioblastoma survival: resistance to treatment and evasion of immune attack.
He argues that miR-181d therapy could extend the survival advantage currently seen only in exceptional cases to a wider group of patients. Published in the journaliScience in March 2026, the work brought together institutions including the University of Minnesota, Johns Hopkins University, and the International Institute of Information Technology.
Planning is underway for a clinical trial testing direct surgical delivery of the molecule into the tumor. Success would establish whether the molecule’s dual mechanism produces durable survival gains for patients beyond the exceptional responder group. This study is likely to provide exciting insights to other companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are also engaged in the quest for better treatments against glioblastoma and other primary and secondary brain cancers.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
